You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

46 Results
Drug
Other Name(s): Suprefact® , Suprefact Depot® , Suprefact Nasal Spray®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Casodex® (multiple brands available)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Yervoy®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2024
Drug
Other Name(s): Treanda®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Adcetris®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2024
Drug
Other Name(s): Bosulif®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Blincyto®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024

Pages